Malaria vaccine shows promise for kids with HIV in new trial
NCT ID NCT05385510
First seen Feb 28, 2026 · Last updated May 08, 2026 · Updated 10 times
Summary
This study tested the safety and immune response of the R21/Matrix-M malaria vaccine in 122 African children aged 5-36 months, both with and without HIV. The goal was to see if the vaccine is safe and triggers a strong immune reaction in children living with HIV. Results will help determine if this vaccine can protect this vulnerable group from malaria.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALARIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
MRC/UVRI & LSHTM Uganda Research Unit
Entebbe, Uganda
Conditions
Explore the condition pages connected to this study.